image descriptionimage description

Disease control may be possible with HUMIRA1-3

HUMIRA has been proven to induce and maintain remission (little or no symptoms) in many people with moderate to severe Crohn’s disease.1-3

If you are still experiencing symptoms your current treatment may not have your moderate to severe Crohn’s disease under control.

Ongoing symptoms can include:

  • abdominal pain which may be cramping and intermittent or feel like a dull, constant ache depending on the location of inflammation
  • a sore abdomen when touched
  • nausea or vomiting
  • unintended weight loss
  • diarrhoea that can occur many times a day
  • fever.

Do you feel like you’ve tried everything? HUMIRA, a biologic medication for moderate to severe Crohn’s disease may be right for you

The government medicine funding agency, PHARMAC, fully subsidises HUMIRA if your Crohn’s disease has not fully responded to other medicines prescribed by a specialist, and you meet other criteria required by PHARMAC. Your specialist will discuss whether HUMIRA is right for you, and whether you may qualify for PHARMAC funded treatment.

If you’re like others who’ve not responded well enough or have lost response to your current Crohn’s disease treatments, such as aminosalicylates, corticosteroids, immunomodulators, or another biologic, ask your gastroenterologist about HUMIRA.

A biologic medicine like HUMIRA works by identifying and blocking a specific source of inflammation, TNF, that contributes to Crohn’s disease symptoms, and it may be an option for some people.

HUMIRA treatment is only available on prescription, so if you are still experiencing symptoms of Crohn’s disease despite your current treatment, you should refer to your gastroenterologist to see if HUMIRA is right for you.

Disease control may be possible with HUMIRA.

Based on clinical trials, it is expected that around half of adults with Crohn’s disease (that have not previously been given a biologic) may clinically respond or achieve remission (little or no symptoms) after just four weeks of starting HUMIRA.1,2 In some people, achieving clinical remission can take longer.

HUMIRA has been studied in clinical trials up to 4 years. Based on clinical trial results with 4 years follow-up, many of those adults who may respond or achieve remission initially with HUMIRA for Crohn’s disease will continue to benefit over time.3

References:
# All experiences, possible outcomes or improvements are hypothetical and based on significant Quality Of Life (QOL) improvements as measured in the listed clinical studies. Use of these references does not imply endorsement or approval by any individual or the authors.

  1. Hanauer S et al. Gastroenterol 2006;130:323–333.
  2. Colombel JF, et al. Gastroenterol. 2007;132(1):52-65.
  3. Panaccione R, et al. Aliment Pharmacol Ther 2013;1-12.

NZ-HUM-0117 TAPS PP9594 Prepared May 2017

Learn how HUMIRA works

Watch this short video to get a better understanding of how HUMIRA targets and helps to block TNF.

How HUMIRA treatment works video transcript

Usually, your immune system defends your body from many of the things that can harm it. But when the system doesn’t work right, it can attack healthy tissues and organs. This is an autoimmune disease. One part of your immune system is a protein called TNF, which is produced naturally by the body’s immune system. But in certain autoimmune diseases, some people produce too much TNF. This often leads to inflammation. HUMIRA is a medication called a TNF blocker. It works by binding to TNF molecules and blocking them from attaching to and making cells behave in a way which leads to effects on health. In this way, HUMIRA helps reduce the damaging effects of excess TNF. Remember, although HUMIRA can’t stop your body’s overproduction of TNF it can reduce its effects.

The immune system can overproduce the TNF protein, which is one source of inflammation that contributes to the symptoms of Crohn’s disease. HUMIRA targets and helps block TNF (a particular protein), reducing its inflammatory effects on the gastrointestinal tract (GI tract or tummy).

Talk to your gastroenterologist about whether HUMIRA is right for treating your Crohn’s disease

References:
# All experiences, possible outcomes or improvements are hypothetical and based on significant Quality Of Life (QOL) improvements as measured in the listed clinical studies. Use of these references does not imply endorsement or approval by any individual or the authors.

  1. Hanauer S et al. Gastroenterol 2006;130:323–333.
  2. Colombel JF, et al. Gastroenterol. 2007;132(1):52-65.
  3. Panaccione R, et al. Aliment Pharmacol Ther 2013;1-12.

NZ-HUM-0117 TAPS PP9594 Prepared May 2017

Find out what you may expect when starting treatment with HUMIRA for moderate to severe Crohn’s disease

Based on clinical study results, more than half of adults with moderate to severe Crohn’s may expect to notice improvement in symptoms after just four weeks of starting HUMIRA, and in some people even earlier1,2.

Start out on the right path by learning how to take HUMIRA correctly

The usual recommended dose for treating Crohn’s disease is an initial dose of 160mg followed by 80mg two weeks after, then 40mg injected every two weeks. Your gastroenterologist will decide what dosage of HUMIRA you require and how often you need to administer the injection. Only inject as prescribed by them.

Humira is given by injection just under the skin. HUMIRA is available in either a pre-filled single use syringe, or pre-filled single-use auto-injector pen and both come pre-loaded with the exact dose of medicine inside, so it comes ready to inject and you can do it by yourself. Your gastroenterologist or nurse will be able to help you and be with you for your first injection however before long you will be able to do it by yourself, or if not, it can be given by another healthcare professional or a family member or friend after they have been trained to give injections. Also, for people on HUMIRA in New Zealand you can join the AbbVie Care support programme with access to a nurse to help you.

Watch these short videos to get a better understanding of how to inject HUMIRA

Pen video also available in the following languages:
Hindi    Simplified Chinese    Samoan    Tongan

NZ-IMM-0046

Syringe video also available in the following languages:    
Hindi    Simplified Chinese    Samoan    Tongan

NZ-IMM-0047

Storage and travelling with HUMIRA

Keep HUMIRA in the outer carton until it is time to use it. HUMIRA must be kept in the refrigerator (+2° C to +8° C) but don’t allow it to freeze. If you are travelling the HUMIRA pre-filled pen or pre-filled syringe may be stored at room temperature (below +25° C) for a maximum period of 14 days, but it must be protected from light. Once removed from the refrigerator for room temperature storage, the syringe or pen must be used within 14 days or discarded even if it is returned to the refrigerator. If additional syringes or pens are being carried, they should be refrigerated (kept between 2°C–8°C).

Join AbbVie Care to receive an ice pack and order a travel wallet through www.abbviecare.co.nz or call 0800 848 243.

When planning to travel overseas it is important that you:

  • talk to your doctor about travelling with HUMIRA
  • carry a letter from your doctor detailing what HUMIRA is, how much you will be taking, and stating that it is for your own personal use
  • leave HUMIRA in its original packaging so it is clearly labeled with your name and dosage instructions (if you are taking HUMIRA pens/syringes with you)


AbbVie Care Support Programme helps take care of you

AbbVie Care is available to you when you are taking HUMIRA. Support from AbbVie Care is designed to complement the care you receive from your specialist and clinic nurse.
AbbVie Care provides personalised support to meet each person’s needs. The aim is by working together people can achieve better outcomes with their health and quality of life.

It’s easy to ENROL

JOIN AbbVie Care to get the best out of your HUMIRA treatment
• Go online to www.abbviecare.co.nz
• Call 0800 848 243

How AbbVie Care supports you:

AbbVie Care Nurse

AbbVie Care Nurse Support

– Home visits or phone calls to help with injecting^
– Scheduled phone calls to provide information and support
– An 0800 number to call when you have a question

www.abbviecare.co.nz

www.AbbVieCare.co.nz

– Helpful resources and tools (ie. travel advice)
– The ability to order your sharps container and travel wallet online
– Medication and appointment reminders
– Visit www.abbviecare.co.nz

AbbvieCare_online-com

Online Community

– Connecting you to others on HUMIRA
– Contact with your AbbVie Care Nurse

AbbvieCare Sharps Disposal Programme

Sharps Disposal Programme

– Delivery of sharps container to safely dispose of your HUMIRA pens and syringes
– Access to pharmacy disposal of your sharps container

AbbvieCare Travel Wallet

Travel Wallet

– Designed to make travelling with HUMIRA safer and easier

Abbvie_Care_Welcome_Kit

Welcome Kit

– Information on all you need to know to get the best out of AbbVie Care
– Ice pack to assist with injecting


References:
All experiences, possible outcomes or improvements are hypothetical and based on significant Quality Of Life (QOL) improvements as measured in the listed clinical studies. Use of these references does not imply endorsement or approval by any individual or the authors.
^Home visits do not cover all of New Zealand. Your AbbVie Care Nurse will be able to discuss this with you when you join AbbVie Care.

  1. Hanauer S et al. Gastroenterol 2006;130:323–333.
  2. Colombel JF, et al. Gastroenterol. 2007;132(1):52-65.
  3. Panaccione R, et al. Aliment Pharmacol Ther 2013;1-12.

NZ-HUM-0117 TAPS PP9594 Prepared May 2017

The following resources have been compiled to help you get support outside the HUMIRA AbbVie Care programme. We hope you find them useful.

Own Your IBDlogo_own_your_ibd

An information portal for New Zealanders with, or caring for someone with, Crohn’s disease or ulcerative colitis, which are both inflammatory bowel diseases (IBD).
www.ownyouribd.co.nz

Crohn’s and Colitis New Zealand (CCNZCrohns and Colitis New Zealand)

Crohn’s and Colitis New Zealand is a charitable trust whose aims are to provide support, advice and information to interested individuals and people who have Crohn’s disease or ulcerative colitis and their families and caregivers.
www.crohnsandcolitis.org.nz

Toilet Map New Zealand

toilet map logo new zealand

For people with Crohn’s disease and ulcerative colitis, finding the nearest available toilet can often be a critical situation. Toilet Map list more than 7,500 public toilets available in New Zealand.

www.toiletmap.co.nz

Food SavvyFOOD SAVVY top_logo1

Food Savvy are a team of NZ Registered Dietitians committed to assisting Kiwis achieve their personal health goals. They are familiar with the pressures of a busy lifestyle. So they understand that getting the balance right in today’s GO GO GO lifestyle can be tough, and requires skill and dedication
www.foodsavvy.co.nz

IBD Passport

ibd passport logo

IBD Passport is an award winning website that aims to provide comprehensive, practical and reliable information on all aspects of travelling with Crohn’s disease or Ulcerative colitis. IBD Passport is the first website to combine this information into one resource to make planning your trip easy.
www.ibdpassport.com/

Australian Crohn’s and Colitis Association

www.acca.net.au

Center for Digestive Diseases Australia

www.cdd.com.au

Crohn’s and Colitis UK

www.crohnsandcolitis.org.uk

Crohn’s and Colitis Foundation of Americal (CCFA)

www.ccfa.org

Colorectal Surgical Society of Australia and New Zealand

www.cssanz.org.au

References:
# All experiences, possible outcomes or improvements are hypothetical and based on significant Quality Of Life (QOL) improvements as measured in the listed clinical studies. Use of these references does not imply endorsement or approval by any individual or the authors.

  1. Hanauer S et al. Gastroenterol 2006;130:323–333.
  2. Colombel JF, et al. Gastroenterol. 2007;132(1):52-65.
  3. Panaccione R, et al. Aliment Pharmacol Ther 2013;1-12.

NZ-HUM-0117 TAPS PP9594 Prepared May 2017